Yuexin Yu
Director
Andera Partners
Paris, France
About
-
Yuexin is director at Life Sciences team based in Paris. He has been involved in portfolio companies including Amolyt (acquired by AZ), ReViral (acquired by Pfizer), LogicBio (acquired by Alexion), Mineralys (MLYS), Artios, Evommune, Tubulis, TargED, and JenaValve.
-
Before joining Andera, Yuexin was at 3H Health Investment Management based in Hong Kong, mainly focusing on investments of biopharma companies headquartered in Asia. He led the investments of InnoCare (HK.9969, SH.688428), KeyMed (HK.2162), RareStone Group, EdiGen, and was involved in the investments of CanSino (HK.6185), HeMo Bioengineering, and Imperative Care.
-
Prior to VC life, Yuexin was part of the life cycle management teams of Remicade and Keytruda at MSD. He started career at bioMérieux in the corporate venture arm in France, and then business development in the portfolio company Biotheranostics (later acquired by Hologic) in the US.
-
Yuexin has bachelor’s degree in pharmacy from SJTU and business degree from HEC Paris. He speaks Chinese, English and French.
My organisation
Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage €4.3 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion/Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).
Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA.
Based in Paris, with offices in Antwerp, Milan and Munich, Andera Partners is wholly owned by its teams, which count nearly 115 professionals, of which 72 investment professionals. It is structured as a partnership and managed by a board of 13 partners.